Psychedelic medicine biotech firm MindMed has announced it has begun a study for a “neutralizer” technology that could shorten and stop the effects of an LSD trip during therapy, paving the way for an “emergency shut-off switch” for psychedelic-assisted therapy.
MindMed has several therapies based on lysergic acid diethylamide (LSD) in the phase 2 for treatment of anxiety and cluster headaches, which would be used as an aid during therapy sessions.
MindMed is one of those companies. The Toronto-based firm is led by JR Rahn, a former Uber executive whose cocaine addiction led him to try psychedelics as a treatment—an experience he credits with saving his life. Rahn believes drugs like LSD could hold the key to helping the millions of people who have been driven to despair by the pandemic.
– MindMed (NEO: MMED) (OTCQB: MMEDF) (DE: MMQ), a leading psychedelic medicine biotech company announced a new partnership with Swiss startup MindShift Compounds AG to develop and patent next-gen psychedelic compounds with psychedelic or empathogenic properties.
